Chapter 9 References
Where possible we have provided additional details of websites referenced, see the Support Directory.
| page | |
| 197 | National newborn screening programme |
| 197 | Neonatal screening |
| 201 | Down’s Syndrome Medical Interest Group |
| 204 | Screening for neuroblastoma |
Page 197: National newborn screening programme
Streetly A,.Corbett V. The national newborn screening programme : an audit of phenylketonuria and congenital hypothyroidism screening in England and Wales. London: Department of Public Health Medicine, UMDS Guy’s and St Thomas’s Medical Schools. 1998.
Page 197: Neonatal screening
Neonatal screening for inborn errors of metabolism: a systematic review. Seymour C A, Thomason M J, R A Chalmers, Addison G M, Bain M D, Cockburn F, Littlejohns P, Lord J, Wilcox A H. Health Technology Assessment 1997; Vol. 1: No. 11.
Neonatal screening for inborn errors of metabolism: cost, yield and outcome. Pollitt R J, Leonard J V, Green A, Nicholl J, McCabe C J, Nicholson P, Booth A, Tunaley J R, Cooper N J, Virdi N K. Health Technology Assessment 1997; Vol. 1: No. 7.
Both can be ordered at www.hta.nhsweb.nhs.uk
Page 201: Down’s Syndrome Medical Interest Group
Down’s Syndrome Medical Interest Group website www.dsmig.org.uk.
Page 204: Screening for neuroblastoma
Woods W G, Tuchman M, Robison L L, et al. A population-based study of the usefulness of screening for neuroblastoma. Lancet 1996;348:1682-87.Bessho F. Where should neuroblastoma mass screening go? Lancet 1996;348:1672
Powell J E, Estève J, Mann J R, et al. Neuroblastoma in Europe: difference in the pattern of disease in the UK. Lancet 1998;352:682-87.
Woods W G. Unravelling mysteries of neuroblastoma. Lancet 1998;352:667-68.
Suita S. Mass screening for neuroblastoma in Japan: Lessons learned and future directions. Journal of Pediatric Surgery 2002;37:949-954.